An Adjunct Test Distinguishing Bacterial From Viral Etiology Improves Resource Utilization and Efficiency in the ED.

Respiratory Tract Infections Clinical Trial

Official title:

Does an Adjunct Diagnostic Test That Can Discriminate Bacterial From Viral Etiology Early in the Management of Respiratory Infections Improve Management Accuracy and Quality in the Acute Care Setting?

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06070688
• Other study ID #: HSC-MS-23-0692
• Status: Recruiting
• Phase: N/A
• Start date: December 11, 2023
• Est. completion date: December 30, 2024

Study information

• Verified date: May 2024
• Source: The University of Texas Health Science Center, Houston
• Contact: David Robinson, MD,MS,MMM
• Phone: (713) 500-7873
• Email: David.J.Robinson[@]uth.tmc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate overall changes in patient management and longer-term resource utilization between control and test arms, including (but not limited to) additional work-up (including other diagnostic tests and consults), antimicrobial treatments, disposition decisions and hospital length of stay (LOS)

Description:

The trial seeks to compare the benefits of adding a diagnostic test that can distinguish the etiology of an acute respiratory illness early in the work-up and management. All adult patients shall be evaluated through the Emergency Department (ED) as an undiagnosed acute reparatory illness (URI). The included patient cohort must present with SIRS criteria and be ill enough to require immediate blood draw and management by the ED. Excluded are any URIs with a predetermined diagnosis or subjects presenting with illness not determined to be a URI as a primary diagnosis. The experimental arm of the study shall have in addition to the standard of care labs and diagnostics, a novel protein array blood test that can distinguish bacterial from viral disease. The control group will not receive these results. The trial seeks to examine the difference in clinical outcomes when a adjunct biomarker than can help the clinician guide more accurate therapy is available early in the diagnostic workup. Benefits are defined in the primary and secondary outcomes as reduced resources expended through reduced laboratory, radiological, blood bank, and pharmaceutical expenditures. Comparative resource utilization costs include changes in hospital and or ED length of stay, lower follow up visits and readmissions, less inpatient and outpatient physician consultants and services called for to manage the patients care, and overall costs. Both primary and secondary outcomes will be used to categorize the costs and resources required to manage the patient. Primary objective is to evaluate overall changes in patient management and longer-term resource utilization between control and test arms, including (but not limited to) additional work-up (including other diagnostic tests and consults), antimicrobial treatments, disposition decisions and hospital length of stay (LOS). The exploratory objective is to evaluate changes between control and test arm in ED LOS, bounce backs (patients returning within 72 hours), work-up costs and the impact of physician seniority.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 30, 2024
• Est. primary completion date: December 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Current disease duration = 7 days

• Temperature = 37.8°C (100°F) or tactile fever, noted at least once within the last 7 days

• Clinical suspicion of bacterial or viral respiratory tract infection (RTI)

• Blood tests are being ordered

Exclusion Criteria:

• Systemic antibiotics taken up to 48 hours prior to presentation

• Outpatient steroids taken within 48 hours prior to presentation

• Suspicion and/or confirmed diagnosis of infectious gastroenteritis/colitis

• Inflammatory disease

• Congenital immune deficiency (CID)

• A proven or suspected infection on the presentation with Mycobacterial ,parasitic or fungal (e.g., Candida, Histoplasma, Aspergillus) pathogen

• Human immunodeficiency virus(HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (self-declared or known from medical records)

• Major trauma and/or burns in the last 7 days

• Major surgery in the last 7 days

• Pregnancy - Self reported or medically confirmed

• Active malignancy - Cancer diagnosed within the previous six months, recurrent, regionally advanced, or metastatic cancer, cancer for which treatment had been administered within six months, or hematological cancer that is not in complete remission.

• Current treatment with immune-suppressive or immune-modulating therapies, at some point in the past 10 days

• Hemodynamically unstable (require life-saving interventions such as vasopressors)

• Patients transferred from another facility who already have a differentiated respiratory illness (known diagnosis e.g., culture positive results)

• Consider unsuitable for the study by the study team

Related Conditions & MeSH terms

• Communicable Diseases
• Infections
• Respiratory Tract Infections

Intervention

Diagnostic Test:
• MeMed BV® biomarker test
one purple top tube of whole blood (2-3 cc) to be used for the MeMed Key® device processing without the need for centrifuge. The MeMed BV® test takes approximately 15 minutes to process and result. After, the sample has been processed and the MeMed BV® test has resulted, the sample of blood will be discarded for each patient enrolled in the study.
• Usual care
Usual care includes diagnostic hematology, chemistry, biomarkers, and culture results along with imaging, consults, and medications, in the treatment of acute viral and/or bacterial illness.

Locations

Country	Name	City	State
United States	The University of Texas Health Science Center at Houston	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
The University of Texas Health Science Center, Houston	MeMed Diagnostics Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cost of any additional diagnostic tests done by a participant	Additional diagnostic tests may include serial complete blood count (CBC)s, additional blood cultures, viral cultures and serial basic metabolic panel (BMP) blood bank	from day of admission to emergency department upto about 28 day follow up
Primary	Cost of any additional consults done by a participant	Comparative metric between the experimental and control groups	from day of day of admission to emergency department upto about 28 day follow up
Primary	Total cost of any antimicrobial treatments by a participant	Comparative metric between the experimental and control groups	end of study (about 28 days from baseline)
Primary	Number of participants that were admitted to the hospital	Comparative metric between the experimental and control groups	end of study (about 28 days from baseline)
Primary	Cost of hospital stay	Total costs defined as all costs including lab and diagnostic services, blood bank, pharmaceuticals, nursing, consultants, and all other services listed in the patient's work-up. Comparative metric between the experimental and control groups	end of study (about 28 days from baseline)
Primary	Length of hospital stay	Comparative metric between the experimental and control groups	at time of discharge( from 28 days- 6months from baseline)
Secondary	Length of stay in emergency department	Comparative metric between the experimental and control groups	at time of discharge from emergency department (upto about 48 hours form admission)
Secondary	Number of participants that had a bounce back as defined as patients returning any time during the 28-day call back period	Bounce backs are defined as any return to a health care entity during the 28 day period after discharge from the index visit. Comparative metric between the experimental and control groups	end of study (about 28 days from baseline)
Secondary	Emergency room work-up costs	Comparative metric between the experimental and control groups	at time of discharge from emergency department (upto about 48 hours form admission)
Secondary	Number of participants with medical interventions such as blood draws, consults and imaging used during the patient's time in the study	Comparative metric between the experimental and control groups	end of study (about 28 days from baseline)
Secondary	Quality of care as determined by the number of acute respiratory ill patients with bacterial etiology that received appropriate antibiotics	Comparative metric between the experimental and control groups	Within 1-3 hours of admission to emergency department
Secondary	Number of participants within the upper respiratory infection (URI) cohort without a bacterial source (viral, inflammatory, etc.) who appropriately did not receive antibiotics or whose antibiotic course was withheld during the patient's time in the study	Comparative metric between the experimental and control groups	end of study (about 28 days from baseline)